Patents by Inventor Anthony T. Maurelli

Anthony T. Maurelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9434772
    Abstract: Recombinant vectors comprising the cell entry region of the Shigella ox EIEC invasion plasmid are provided, as well as, Shigella or EIEC strains comprising the recombinant vectors. The vectors provide an improved platform for developing attenuated vaccine strains of Shigella or EiEC and for delivering other foreign proteins of interest. The recombinant vectors and bacterial strains comprising the same may be used in methods of inducing an immune response.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 6, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventor: Anthony T. Maurelli
  • Publication number: 20140220072
    Abstract: Recombinant vectors comprising the cell entry region of the Shigella ox EIEC invasion plasmid are provided, as well as, Shigella or EIEC strains comprising the recombinant vectors. The vectors provide an improved platform for developing attenuated vaccine strains of Shigella or EiEC and for delivering other foreign proteins of interest. The recombinant vectors and bacterial strains comprising the same may be used in methods of inducing an immune response.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 7, 2014
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC
    Inventor: Anthony T. Maurelli
  • Patent number: 6780414
    Abstract: “Black holes” in the genomes of bacterial pathogens represent deletions of “anti-virulence” genes, i.e. genes that are detrimental to a pathogenic lifestyle. Identification of the missing genetic loci in the “black hole” identifies genes that are incompatible with the bacteria's pathogenicity. These genes, their gene products, and compounds generated by the enzymatic action of these gene products represent potential new compounds that are inhibitory to the bacterial pathogen and thus useful as pharmaceuticals. The utility of this concept is demonstrated in the missing gene for lysine decarboxylase, and the resulting inhibitory activity of cadaverine (the diaminoalkyl reaction product of lysine decarboxylase) on the Shigella enterotoxins. Diaminoalkyl compounds are therefore potent inhibitors of E. coli and Shigella spp. enterotoxins. Lysine decarboxylase generated from the gene cadA results in attenuation of the enterotoxic effects.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: August 24, 2004
    Assignees: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The University of Maryland, Baltimore, The Regents of the University of Michigan
    Inventors: Anthony T. Maurelli, Reinaldo E. Fernández, Craig A. Bloch, Alessio Fasano
  • Publication number: 20020192225
    Abstract: “Black holes” in the genomes of bacterial pathogens represent deletions of “anti-virulence” genes, i.e. genes that are detrimental to a pathogenic lifestyle. Identification of the missing genetic loci in the “black hole” identifies genes that are incompatible with the bacteria's pathogenicity. These genes, their gene products, and compounds generated by the enzymatic action of these gene products represent potential new compounds that are inhibitory to the bacterial pathogen and thus useful as pharmaceuticals. The utility of this concept is demonstrated in the missing gene for lysine decarboxylase, and the resulting inhibitory activity of cadaverine (the diaminoalkyl reaction product of lysine decarboxylase) on the Shigella enterotoxins. Diaminoalkyl compounds are therefore potent inhibitors of E. coli and Shigella spp. enterotoxins Lysine decarboxylase generated from the gene cadA results in attenuation of the enterotoxic effects.
    Type: Application
    Filed: January 3, 2002
    Publication date: December 19, 2002
    Inventors: Anthony T. Maurelli, Reinaldo E. Fernandez, Craig A. Bloch, Alessio Fasano
  • Patent number: 6344201
    Abstract: “Black holes” in the genomes of bacterial pathogens represent deletions of “anti-virulence” genes, i.e. genes that are detrimental to a pathogenic lifestyle. Identification of the missing genetic loci in the “black hole” identifies genes that are incompatible with the bacteria's pathogenicity. These genes, their gene products, and compounds generated by the enzymatic action of these gene products represent potential new compounds that are inhibitory to the bacterial pathogen and thus useful as pharmaceuticals. The utility of this concept is demonstrated in the missing gene for lysine decarboxylase, and the resulting inhibitory activity of cadaverine (the diaminoalkyl reaction product of lysine decarboxylase) on the Shigella enterotoxins. Diaminoalkyl compounds are therefore potent inhibitors of E. coli and Shigella spp. enterotoxins. Lysine decarboxylase generated from the gene cadA results in attenuation of the enterotoxic effects.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: February 5, 2002
    Inventors: Anthony T. Maurelli, Reinaldo E. Fernández, Craig A. Bloch, Alessio Fasano
  • Patent number: 6342352
    Abstract: The present invention relates to our discovery that the mxiM protein of Shigella flexneri is indispensable for the spread of Shigella from cell to cell. Thus, the invention provides the mxiM protein or peptides or portions thereof as antigens in vaccines to prevent Shigella infections and treat hosts infected with Shigella by inhibiting intercellular spread. In another aspect, the invention relates to antibodies generated against the mxiM proteins, peptides, or portions thereof to detect Shigella in contaminated food and water supplies as well as in infected hosts. The present invention also describes a method called the TIER (test of intracellular expression requirements) for determining the intracellular expression requirements of genes and therefore, permitting one to establish the role of genes in the pathogenesis of organisms. A method of detecting Shigella or Shigella mxiM DNA in a sample using a mxiM DNA probe is also described.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: January 29, 2002
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventors: Raymond Schuch, Robin C. Sandlin, Anthony T. Maurelli